
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Buenos Aires, Argentina — WorldNow reports that researchers in Argentina have successfully tested a new vaccine to prevent recurrence of melanoma.